Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q99879: Variant p.His110Tyr

Histone H2B type 1-M
Gene: H2BC14
Feedback?
Variant information Variant position: help 110 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help US The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Histidine (H) to Tyrosine (Y) at position 110 (H110Y, p.His110Tyr). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and polar (H) to large size and aromatic (Y) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description: help In a colorectal cancer sample; somatic mutation. Any additional useful information about the variant.


Sequence information Variant position: help 110 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 126 The length of the canonical sequence.
Location on the sequence: help ITSREIQTAVRLLLPGELAK H AVSEGTKAVTKYTSSK The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human                         ITSREIQTAVRLLLPGELAKHAVSEGTKAVTKYTSSK

Mouse                         ITSREIQTAVRLLLPGELAKHAVSEGTKAVTKYTSSK

Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 2 – 126 Histone H2B type 1-M
Modified residue 93 – 93 Omega-N-methylarginine
Modified residue 109 – 109 N6-(2-hydroxyisobutyryl)lysine; alternate
Modified residue 109 – 109 N6-glutaryllysine; alternate
Modified residue 109 – 109 N6-lactoyllysine; alternate
Modified residue 109 – 109 N6-methyllysine; alternate
Modified residue 116 – 116 Phosphothreonine
Modified residue 117 – 117 N6-(2-hydroxyisobutyryl)lysine; alternate
Modified residue 117 – 117 N6-(beta-hydroxybutyryl)lysine; alternate
Modified residue 117 – 117 N6-glutaryllysine; alternate
Modified residue 117 – 117 N6-lactoyllysine; alternate
Modified residue 117 – 117 N6-malonyllysine; alternate
Modified residue 117 – 117 N6-methylated lysine; alternate
Modified residue 117 – 117 N6-succinyllysine; alternate
Modified residue 121 – 121 N6-(2-hydroxyisobutyryl)lysine; alternate
Modified residue 121 – 121 N6-(beta-hydroxybutyryl)lysine; alternate
Modified residue 121 – 121 N6-glutaryllysine; alternate
Modified residue 121 – 121 N6-lactoyllysine; alternate
Modified residue 121 – 121 N6-succinyllysine; alternate
Glycosylation 113 – 113 O-linked (GlcNAc) serine
Cross 121 – 121 Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin); alternate



Literature citations
The consensus coding sequences of human breast and colorectal cancers.
Sjoeblom T.; Jones S.; Wood L.D.; Parsons D.W.; Lin J.; Barber T.D.; Mandelker D.; Leary R.J.; Ptak J.; Silliman N.; Szabo S.; Buckhaults P.; Farrell C.; Meeh P.; Markowitz S.D.; Willis J.; Dawson D.; Willson J.K.V.; Gazdar A.F.; Hartigan J.; Wu L.; Liu C.; Parmigiani G.; Park B.H.; Bachman K.E.; Papadopoulos N.; Vogelstein B.; Kinzler K.W.; Velculescu V.E.;
Science 314:268-274(2006)
Cited for: VARIANT [LARGE SCALE ANALYSIS] TYR-110;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.